Sysmex Corporation (TYO:6869)
| Market Cap | 1.11T -5.5% |
| Revenue (ttm) | 524.95B +4.5% |
| Net Income | 39.60B -16.1% |
| EPS | 63.79 -15.7% |
| Shares Out | 605.20M |
| PE Ratio | 28.87 |
| Forward PE | 25.91 |
| Dividend | 40.00 (2.06%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 1,782,400 |
| Open | 1,838.00 |
| Previous Close | 1,821.50 |
| Day's Range | 1,812.00 - 1,844.00 |
| 52-Week Range | 1,246.00 - 2,012.50 |
| Beta | 0.71 |
| Analysts | Buy |
| Price Target | 2,060.71 (+11.9%) |
| Earnings Date | Nov 10, 2026 |
About Sysmex
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. T... [Read more]
Financial Performance
In fiscal year 2026, Sysmex's revenue was 500.01 billion, a decrease of -1.70% compared to the previous year's 508.64 billion. Earnings were 35.46 billion, a decrease of -33.93%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for 6869 stock is "Buy." The 12-month stock price target is ¥2,061, which is an increase of 11.90% from the latest price.
News
Q1 2027 Sysmex Corp Earnings Presentation Transcript
Q1 2027 Sysmex Corp Earnings Presentation Transcript
Sysmex Earnings Call Transcript: Q1 2027
Sales and profits surged in Q1, led by robust growth in the Americas and favorable FX, while China faced continued declines due to healthcare policies. Upward revisions were made to first half and full year forecasts, with risks from China’s policy changes and one-time expenses factored in.
Sysmex Quarterly report: Q1 2027
Sysmex has published its Q1 2027 quarterly earnings report on August 7, 2026.
Sysmex Slides: Q1 2027
Sysmex has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 7, 2026.
Sysmex Slides: Investor presentation
Sysmex has posted slides in relation to its latest quarterly earnings report, which was published on June 30, 2026.
Sysmex Earnings Call Transcript: Q4 2026
New management is prioritizing performance recovery, transparency, and disciplined capital allocation after missing previous targets. Despite profit declines driven by China and one-time impairments, growth continues in Americas, EMEA, and AP, with dividends and buybacks maintained.
Sysmex Quarterly report: Q4 2026
Sysmex has published its Q4 2026 quarterly earnings report on May 14, 2026.
Sysmex Slides: Q4 2026
Sysmex has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 14, 2026.
Sysmex Transcript: Investor update
The midterm management plan prioritizes deepening diagnostics, digital transformation, and global expansion, with ambitious financial targets and a focus on innovation in AI, R&D, and regenerative medicine. Strategic capital allocation and ESG initiatives support sustainable growth.
Sysmex Slides: Investor update
Sysmex has posted slides in relation to its latest quarterly earnings report, which was published on March 13, 2026.
Sysmex Earnings Call Transcript: Q3 2026
Sales and profits declined year-over-year due to weak China demand, tariffs, and inventory adjustments, prompting a downward revision of full-year forecasts. Americas and EMEA regions showed strong growth, while China and Japan faced significant headwinds.
Sysmex Quarterly report: Q3 2026
Sysmex has published its Q3 2026 quarterly earnings report on February 12, 2026.
Sysmex Slides: Q3 2026
Sysmex has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 12, 2026.
Sysmex Earnings Call Transcript: Q2 2026
First half results saw declines in revenue and profit due to Japan's ecosystem transition, inventory devaluation, and a challenging Chinese market, while overseas regions excluding China performed well. Full-year forecasts were revised down, but growth is expected in emerging markets and new business areas.
Sysmex Quarterly report: Q2 2026
Sysmex has published its Q2 2026 quarterly earnings report on November 5, 2025.
Sysmex Slides: Q2 2026
Sysmex has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 5, 2025.
Sysmex upgraded to Buy from Hold at Jefferies
Jefferies analyst Stephen Barker upgraded Sysmex to Buy from Hold with a price target of 3,100 yen, up from 2,700 yen. The company’s China outlook stabilizing and India is “taking…